lixisenatide

New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
FDA approves lixisenatide for type 2 diabetesNew drug review
New diabetes drug up against leading brandsFDA approved lixisenatide (Adlyxin, Sanofi-Aventis), a once-daily mealtime GLP-1 receptor agonist injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity, Eli Lilly) and the injectable liraglutide (Victoza, Novo Nordisk).